’ net profit increased 19 per cent to ₹279 crore in the fourth quarter ended March 31, 2026, compared to ₹234 crore in the corresponding quarter of the previous financial year.
The total revenue of the Hyderabad-based company increased 5 per cent to ₹1,812 crore against ₹1,720 crore in the year-ago period.
“We significantly accelerated our performance in FY26, delivering strong revenue growth and expanded profitability, backed by successful commercial supplies for NCE programmes, new launches ramp-up and sustained leadership in Anti-retroviral segment,’’ Satyanarayana Chava, Founder & Chief Executive Officer, Laurus Labs, said in a release.
“The transformation of our portfolio is well underway, and momentum is building. We are making significant investments in novel technologies, scale and strengthening integrated capabilities offerings towards laying the foundation for future growth,’’ Chava added.
For the full year, the company posted 23 per cent growth in revenue at ₹6,813 crore (₹5,554 crore) while the net profit more than doubled to ₹889 crore (₹358 crore). “Overall, we reported strong FY26 performance, reflecting continued robust demand for integrated offerings across CDMO and Affordable Medicines business,’’ V V Ravi Kumar, Executive Director & Chief Financial Officer, said.